secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2026-02-20T23:59:59+00:00
Accession:  0001493152-26-007587
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell transfers exclusive sCD80 license to BriaPro; receives 23.97M shares, increases stake to 78%
--------------------------------------------------------------------------------

- BriaCell transfers exclusive license for Soluble CD80 to BriaPro for 23,972,589 BriaPro shares, increasing stake to ~78%.
- BriaCell provides up to $3M credit facility to BriaPro for R&D; each drawdown subject to BriaCell approval.
- Transaction expected to close March 12, 2026, subject to disinterested shareholder approval and independent valuation.
- License originally from University of Maryland Baltimore County; sCD80 showed anti-tumor activity in animal models.
- BriaPro stock valued at approx. C$1.18M aggregate; BriaPro to pay 2% royalties to UMBC upon commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315226007587/0001493152-26-007587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315226007587/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-007587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer